News & Updates

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

02 Jul 2024 by

Vaginal estrogen therapy may be safely used to treat genitourinary symptoms in early-stage breast cancer patients with HR-negative tumours and in those concurrently treated with tamoxifen, according to the results of a target trial emulation. However, its use may be detrimental to disease-free survival (DFS) outcomes in patients receiving aromatase inhibitors.

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

02 Jul 2024

Novel personalized cancer vaccine may delay relapse in HNSCC

02 Jul 2024 by

TG4050, a novel viral-based personalized cancer vaccine, showed promise in a phase I trial presented during a late-breaking poster presentation at AACR 2024. The investigational vaccine induced polyepitopic immune responses against private neoantigens in resected HPV-negative head and neck squamous cell cancer (HNSCC).

Novel personalized cancer vaccine may delay relapse in HNSCC

02 Jul 2024

D-VCd: The 1st FDA-approved AL amyloidosis treatment

02 Jul 2024 by

AL amyloidosis is a progressive, underdiagnosed disease with multiorgan involvement. Watch this video to gain insights from Dr Herman Liu (Specialist in haematology in Hong Kong) on establishing an early and accurate diagnosis and the recent change in the treatment landscape of AL amyloidosis.

D-VCd: The 1st FDA-approved AL amyloidosis treatment

02 Jul 2024

Exercise boosts sexual health in metastatic breast cancer patients

01 Jul 2024 by

Working out can improve sexual function as well as reduce endocrine sexual symptoms in patients with metastatic breast cancer (mBC), according to data from the PREFERABLE-EFFECT trial.

Exercise boosts sexual health in metastatic breast cancer patients

01 Jul 2024

Wasting disorders overlooked in older adults with cancer

01 Jul 2024

Many wasting disorders remain under-recognized and undertreated among older adults with cancer, and there exists a need to properly identify and manage these conditions, suggests a study.

Wasting disorders overlooked in older adults with cancer

01 Jul 2024

ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board

01 Jul 2024 by

A triplet regimen comprising the anti-CD30 antibody-drug conjugate (ADC) brentuximab vedotin (BV) plus lenalidomide and rituximab (R2) inches its way into the R/R DLBCL* treatment path in the prespecified interim analysis of the ECHELON-3 trial, further reinforcing the role of BV in lymphoma treatment.

ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board

01 Jul 2024

Low-carb, high-protein diet may increase liver cancer risk

01 Jul 2024

Individuals with diets high in animal fat and protein and low in carbohydrates appear to be at heightened risk of hepatocellular carcinoma (HCC), according to a Singapore study.

Low-carb, high-protein diet may increase liver cancer risk

01 Jul 2024

KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC

28 Jun 2024 by

Findings from the phase III KRYSTAL-12 trial underpin the treatment potential of adagrasib for previously treated metastatic non-small cell lung cancer (NSCLC) harbouring a KRAS^G12C mutation.

KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC

28 Jun 2024

Updated KEYNOTE-942: mRNA-4157 plus pembrolizumab sustains RFS, DMFS benefit in melanoma

28 Jun 2024 by

Adjuvant treatment with mRNA-4157 and pembrolizumab led to sustained improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) at approximately 3 years in individuals with resected high-risk melanoma as opposed to pembrolizumab alone, according to the updated results of the phase II KEYNOTE-942 trial presented at ASCO 2024.

Updated KEYNOTE-942: mRNA-4157 plus pembrolizumab sustains RFS, DMFS benefit in melanoma

28 Jun 2024

Sotorasib-panitumumab combo shows positive OS trend in mCRC

26 Jun 2024 by

The combination regimen comprising sotorasib and panitumumab demonstrates a trend towards an improvement in overall survival (OS) compared with investigator’s choice of therapy among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) who had progressed on systemic therapy, according to the OS analysis of the CodeBreak 300 trial presented at ASCO 2024.

Sotorasib-panitumumab combo shows positive OS trend in mCRC

26 Jun 2024

News & Updates

Filter by Specialty:

Specialty:

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

Vaginal estrogen therapy safe for some breast cancer patients, but may pose risk for others

Novel personalized cancer vaccine may delay relapse in HNSCC

Novel personalized cancer vaccine may delay relapse in HNSCC

D-VCd: The 1st FDA-approved AL amyloidosis treatment

D-VCd: The 1st FDA-approved AL amyloidosis treatment

Exercise boosts sexual health in metastatic breast cancer patients

Exercise boosts sexual health in metastatic breast cancer patients

Wasting disorders overlooked in older adults with cancer

Wasting disorders overlooked in older adults with cancer

ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board

ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board

Low-carb, high-protein diet may increase liver cancer risk

Low-carb, high-protein diet may increase liver cancer risk

KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC

KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC

Updated KEYNOTE-942: mRNA-4157 plus pembrolizumab sustains RFS, DMFS benefit in melanoma

Updated KEYNOTE-942: mRNA-4157 plus pembrolizumab sustains RFS, DMFS benefit in melanoma

Sotorasib-panitumumab combo shows positive OS trend in mCRC

Sotorasib-panitumumab combo shows positive OS trend in mCRC